Double-blind clinical assessment of the efficacy of a 4% nicotinamide gel (Exfoliac® NC Gel) versus a 4% erythromycin gel in the treatment of moderate acne with a predominant inflammatory component;Évaluation clinique en double aveugle de l'efficacité d'un gel de nicotinamide 4 % (Exfoliac® NC Gel) versus gel d'érythromycine 4 % dans la prise en charge des acnés modérées à composante inflammatoire prédominante

Nouvelles Dermatologiques

Volumn 23, Issue 7 I, 2004, Pages 385-394

  Weltert, Y ^a   Chartier, S ^a   Gibaud, C ^a   Courau, S ^b   Pechenart, P ^b   Sirvent, A ^a   Girard, F ^a  

^a Pharmascan   (France)

^b Merck Médication Familiale ^*  (France)

Author keywords

Acne; Clinical trial; Erythromycine; Nicotinamide

Indexed keywords

CLINDAMYCIN; ERYTHROMYCIN; EXFOLIAC; NICOTINAMIDE;

ACNE; ADOLESCENT; ADULT; CLINICAL EXAMINATION; CLINICAL TRIAL; COMEDO; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERANCE; FEMALE; GEL; HUMAN; MAJOR CLINICAL STUDY; MALE; PAPULE; PUSTULE; RANDOMIZED CONTROLLED TRIAL; REVIEW; SCORING SYSTEM; SEBORRHEA; SIDE EFFECT;

EID: 4944230282     PISSN: 07525370     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (19)

1. Thiboutot DM. An overview of acne and its treatment. Cutis 1996; 57 (Suppl. 1): 8-12.
2. Oberemok SS, Shalita AR. Acne vulgaris. I. Pathogenesis and diagnosis. Cutis 2002; 70: 101-5.
3. Dreno B, Bodokh I, Chivot M et al. ECLA grading: a system of acne classification for every day dermatological practice. Ann Dermatol Venereol 1999; 126: 136-41.
4. Shalita AR, Smith JG, Parish LC et al. Topical nicotinamide compared with clindamycin gel in the treatment of inflammatory acne vulgaris. Int J Dermatol 1995; 34: 434-7.
5. Bernstein JE, Shalita AR. Topically applied erythromycin in inflammatory acne. J Am Acad Dermatol 1980; 2: 318-21.
6. Pochi PE, Bagatell FK, Ellis CN et al. Erythromycin 2 percent gel in the treatment of acne vulgaris. Cutis 1988; 41: 132-6.
7. Jain A, Sangal L, Basal E et al. Anti-inflammatory effects of erythromycin and tetracycline on Propionibacterium acnes induced production of chemotactic factors and reactive oxygen species by human neutrophils. Dermatol Online J 2002; 8: 2.
8. Leyden JJ, McGinley KJ, Cavalieri S et al. Propionibacterium acnes resistance to antibiotics in acne patients. J Am Acad Dermatol 1983; 8: 41-5.
9. Sofman MS, Shalita AR. Topical antibiotic treatment of acne. In: Marks R, Plewig G., eds. Acne and related disorders. Martin Dunitz Ed. 1988: 77-80.
10. Toyoda M, Morohashi M. An overview of topical antibiotics for acne treatment. Dermatology 1998; 196: 130-4.
11. Griffiths CEM. Nicotinamide 4% gel for the treatment of inflammatory acne vulgaris. J Dermatol Treatment 1995; 6: S8-10.
12. Bekier E, Maslinski C. Antihistaminic action of nicotinamide. Agents Actions 1974; 4: 196.
13. Berk MA, Lorincz AL. The treatment of bullous pemphigoid with tetracycline and niacinamide. A preliminary report. Arch Dermatol 1986; 122: 670-4.
14. Bekier E, Wyczolkowska J, Szyc H, Maslinski C. The inhibitory effect of nicotinamide on asthma-like symptoms and eosinophilia in guinea pigs, anaphylactic mast cell degranulation in mice, and histamine release from rat isolated peritoneal mast cells by compound 48-80. Int Arch Allergy Appl Immunol 1974; 47: 737-48.
15. Ludwig A, Dietel M, Schafer G et al. Nicotinamide and nicotinamide analogues as antitumor promoters in mouse skin. Cancer Res 1990; 50: 2470-5.
16. Bernstein JE, Lorincz AL. The effects of topical nicotinamide, tetracycline and dapsone on potassium iodide-induced inflammation. J Invest Dermatol 1980; 74: 257-8.
17. Fivenson DP, Breneman DL, Rosen GB et al. Nicotinamide and tetracycline therapy of bullous pemphigoid. Arch Dermatol 1994; 130: 753-8.
18. Zemtsov A, Neldner KH. Successful treatment of dermatitis herpetiformis with tetracycline and nicotinamide in a patient unable to tolerate dapsone. J Am Acad Dermatol 1993; 28: 505-6.
19. Handfield-Jones S, Jones S, Peachey R. High dose nicotinamide in the treatment of necrobiosis lipoidica. Br J Dermatol 1988; 118: 693-6.